Analytical research on early-stage and longevity biotech — through an ROI × healthspan lens

As an investor, looking for a financial return is standard. What’s new is the ability to also ask:
“If this works, could it meaningfully extend healthy life?”

Everlife Capital publishes educational research on early-stage and longevity-focused biotech companies, looking at:
Scientific and clinical rationale
Development and regulatory plans
Commercial and payer realities
And a simple ROI × healthspan mental framework

This is not a fund pitch and not individualized investment advice. It’s one investor’s attempt to think rigorously about where future therapies might both create value and improve healthspan.

Subscribe for Free Research Notes
A hand points to colorful business charts and graphs on a paper sheet on a wooden desk.

WHY THIS EXISTS

I found it hard to get both sides of the question in one place:

1. “Could this be a good investment if things go right?”
2. “If it works, how much could it realistically move the needle on healthy years of life?”

So I started Everlife Capital as a research project.

I use my background in engineering and 23+ years of company leadership to build simple, transparent checklists for evaluating early-stage biotech. I apply those checklists to real companies and programs.

And I track it all via a simulated (“paper”) $2.5 million portfolio, so that readers can see how the framework behaves over time—without confusing it with actual client accounts or investment products. You’ll see case studies, checklists, and “gates” for science, CMC, endpoints, payer/IP, and capital efficiency. The goal is to make the thinking visible, not to tell anyone what to buy or sell.

$2.5M SIMULATED FUND

A transparent, simulated $2.5M “paper” fund To pressure-test the framework, I track a hypothetical portfolio (“Everlife Capital Fund I”) with an initial notional size of $2.5M.

Positions are paper entries only, not real trades. There is no pooled vehicle and no capital accepted from subscribers. Entries, notional position sizes, and follow-up notes are shared so readers can see the full decision process, including mistakes.

Any overlaps between companies discussed here and securities held by me or entities I control are disclosed, but the simulated portfolio itself is for educational and illustrative purposes only, not performance marketing. Subscribe to follow new research notes, company write-ups, and updates on how the framework is evolving.

Scroll to Top